VisMederi is pleased to announce the publishing of a collaborative study with GVGH (GSK Vaccines Institute for Global Health) that highlights a significant achievement in vaccine research. This recent study, published in Frontiers in Immunology, describes the creation and validation of a novel enzyme-linked immunosorbent test (ELISA) for quantifying Vi-specific IgG in clinical samples.
Addressing an Essential Requirement
Vaccines aimed at Salmonella Typhi, the pathogen responsible for typhoid illness, are essential for public health initiatives in endemic areas. These vaccines target the Vi capsular polysaccharide, a crucial antigen that aids the immune system in combating the infection. With the integration of these vaccines into standard immunization programs, there is an increasing demand for reliable, high-throughput, and economical assays to assess the immune response, namely the concentrations of Vi-specific IgG in human serum.
The Assay: Accuracy and Efficacy
The research delineates the validation of a novel ELISA for measuring Vi-specific IgG, showcasing its accuracy, linearity, and specificity. The assay underwent thorough testing and was compared to a commercially available anti-Vi ELISA, demonstrating similar performance. The result underscores the assay’s promise as a dependable instrument for assessing immune responses in clinical investigations and facilitating vaccine development.
A Progression in Vaccine Advancement
This assay is already employed to evaluate immunological responses in clinical trials and shows significant potential for advancing research in the field. Its economical and scalable design guarantees widespread implementation in laboratories performing immunogenicity investigations, especially in resource-limited environments where such tools are critically required.
